Schizophrenia

Olanzapine is an atypical antipsychotic, for the treatment of: schizophrenia, manic episodes associated with bipolar disorder and preventing recurrence in bipolar disorder; depressive episodes associated with bipolar disorder, (as part of the Symbyax formulation with fluoxetine),. Olanzapine has also some Off-label uses such as generalized anxiety disorder, panic disorder, post-traumatic stress disorder The schizophrenia market is growing slowly until 2011 to reach $4.3 billion across the 7 Major Markets .

APR developed the proprietary RapidFilm™ technology which is a novel, non-mucoadhesive, fast dissolving oral dosage form based on a water soluble polymer. Placed on top of the tongue, the film disperses within seconds (water is not needed), promoting a gastrointestinal absorption comparable to immediate release oral solid dosage forms

The Olanzapine RapidFilm™ was especially designed for higher patient compliance, by the means of: Ensuring delivery of the drug to patients, once the RapidFilm™ is put on the tongue there is no possibility for the patient to avoid drug delivery and providing the quickest, easiest and most patient friendly way for the oral intake of drugs.